Dapagliflozin
D1692C00005
Phase 3 small_molecule completed
Quick answer
Dapagliflozin for Type 2 Diabetes Mellitus is a Phase 3 program (small_molecule) at AstraZeneca with 2 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed